LBA20 Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial

R. Jones,A. Casbard, M. Carucci, J. Smith, K. Ingarfield,J.M.W. Gee, Z. Hudson, F. Alchami,L. Hayward, T. Hickish,D. Hwang,K. McAdam, S. Spensley, S. Waters,D. Wheatley,M. Beresford

Annals of Oncology(2020)

引用 0|浏览45
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要